Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis

References

1. 1.↵
   1. Pirko I,
   2. Lucchinetti CF,
   3. Sriram S,
   4. et al

   . Gray matter involvement in multiple sclerosis. Neurology 2007; 68: 634– 42

   Abstract/FREE Full Text
2. 2.↵
   1. Poloni G,
   2. Minagar A,
   3. Haacke EM,
   4. et al

   . Recent developments in imaging of multiple sclerosis. Neurologist 2011; 17: 185– 204

   CrossRefPubMed
3. 3.↵
   1. Geurts JJ,
   2. Stys PK,
   3. Minagar A,
   4. et al

   . Gray matter pathology in (chronic) MS: modern views on an early observation. J Neurol Sci 2009; 282: 12– 20

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Geurts JJ,
   2. Pouwels PJ,
   3. Uitdehaag BM,
   4. et al

   . Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 2005; 236: 254– 60

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Fisniku LK,
   2. Chard DT,
   3. Jackson JS,
   4. et al

   . Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008; 64: 247– 54

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Benedict R,
   2. Bruce J,
   3. Dwyer M,
   4. et al

   . Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol 2006; 63: 1301– 06

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Fisher E,
   2. Lee JC,
   3. Nakamura K,
   4. et al

   . Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008; 64: 255– 65

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Ramasamy DP,
   2. Benedict RH,
   3. Cox JL,
   4. et al

   . Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study. J Neurol Sci 2009; 282: 47– 54

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Audoin B,
   2. Ibarrola D,
   3. Malikova I,
   4. et al

   . Onset and underpinnings of white matter atrophy at the very early stage of multiple sclerosis: a two-year longitudinal MRI/MRSI study of corpus callosum. Mult Scler 2007; 13: 41– 51

   Abstract/FREE Full Text
10. 10.↵
    1. Audoin B,
    2. Zaaraoui W,
    3. Reuter F,
    4. et al

    . Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. J Neurol Neurosurg Psychiatry 2010; 81: 690– 95

    Abstract/FREE Full Text
11. 11.↵
    1. Calabrese M,
    2. Atzori M,
    3. Bernardi V,
    4. et al

    . Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol 2007; 254: 1212– 20

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Fisniku LK,
    2. Altmann DR,
    3. Cercignani M,
    4. et al

    . Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis. Mult Scler 2009; 15: 668– 77

    Abstract/FREE Full Text
13. 13.↵
    1. Henry RG,
    2. Shieh M,
    3. Amirbekian B,
    4. et al

    . Connecting white matter injury and thalamic atrophy in clinically isolated syndromes. J Neurol Sci 2009; 282: 61– 66

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Henry RG,
    2. Shieh M,
    3. Okuda DT,
    4. et al

    . Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 2008; 79: 1236– 44

    Abstract/FREE Full Text
15. 15.↵
    1. Raz E,
    2. Cercignani M,
    3. Sbardella E,
    4. et al

    . Clinically isolated syndrome suggestive of multiple sclerosis: voxelwise regional investigation of white and gray matter. Radiology 2010; 254: 227– 34

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Roosendaal SD,
    2. Bendfeldt K,
    3. Vrenken H,
    4. et al

    . Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler 2011; 17: 1098– 106

    Abstract/FREE Full Text
17. 17.↵
    1. Calabrese M,
    2. Rinaldi F,
    3. Mattisi I,
    4. et al

    . The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011; 77: 257– 63

    Abstract/FREE Full Text
18. 18.↵
    1. Dalton CM,
    2. Chard DT,
    3. Davies GR,
    4. et al

    . Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127: 1101– 07

    Abstract/FREE Full Text
19. 19.↵
    1. Raz E,
    2. Cercignani M,
    3. Sbardella E,
    4. et al

    . Gray- and white-matter changes 1 year after first clinical episode of multiple sclerosis: MR imaging. Radiology 2010; 257: 448– 54

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Rocca MA,
    2. Agosta F,
    3. Sormani MP,
    4. et al

    . A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol 2008; 255: 683– 91

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Ceccarelli A,
    2. Rocca MA,
    3. Pagani E,
    4. et al

    . A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. Neuroimage 2008; 42: 315– 22

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Havrdova E,
    2. Zivadinov R,
    3. Krasensky J,
    4. et al

    . Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler 2009; 15: 965– 76

    Abstract/FREE Full Text
23. 23.↵
    1. Horakova D,
    2. Zivadinov R,
    3. Weinstock-Guttman B,
    4. et al

    . HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. J Neuroimmunol 2011; 236: 76– 80

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Poser CM,
    2. Paty DW,
    3. Scheinberg L,
    4. et al

    . New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227– 31

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Zivadinov R,
    2. Rudick RA,
    3. De Masi R,
    4. et al

    . Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57: 1239– 47

    Abstract/FREE Full Text
26. 26.↵
    1. Gelineau-Morel R,
    2. Tomassini V,
    3. Jenkinson M,
    4. et al

    . The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis. Hum Brain Mapp 2011 Oct 5. [Epub ahead of print]
27. 27.↵
    1. Yeh EA,
    2. Weinstock-Guttman B,
    3. Ramanathan M,
    4. et al

    . Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain 2009; 132: 3392– 400

    Abstract/FREE Full Text
28. 28.↵
    1. Patenaude B,
    2. Smith S,
    3. Kennedy D,
    4. et al

    . A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 201;56:907– 22
29. 29.↵
    1. Batista S,
    2. Zivadinov R,
    3. Hoogs M,
    4. et al

    . Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol 2012; 259: 139– 46

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Sicotte NL,
    2. Kern KC,
    3. Giesser BS,
    4. et al

    . Regional hippocampal atrophy in multiple sclerosis. Brain 2008; 131: 1134– 41

    Abstract/FREE Full Text
31. 31.↵
    1. Houtchens MK,
    2. Benedict RH,
    3. Killiany R,
    4. et al

    . Thalamic atrophy and cognition in multiple sclerosis. Neurology 2007; 69: 1213– 23

    Abstract/FREE Full Text
32. 32.↵
    1. Polman C,
    2. Kappos L,
    3. Freedman MS,
    4. et al

    . Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. J Neurol 2008; 255: 480– 87

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Gold R,
    2. Wolinsky JS,
    3. Amato MP,
    4. et al

    . Evolving expectations around early management of multiple sclerosis. Ther Adv Neurol Disord 2010; 3: 351– 67

    Abstract/FREE Full Text
34. 34.↵
    1. Filippi M,
    2. Horsfield MA,
    3. Morrissey SP,
    4. et al

    . Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994; 44: 635– 41

    Abstract/FREE Full Text
35. 35.↵
    1. Benedict RH,
    2. Ramasamy D,
    3. Munschauer F,
    4. et al

    . Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. J Neurol Neurosurg Psychiatry 2009; 80: 201– 06

    Abstract/FREE Full Text
36. 36.↵
    1. Kiy G,
    2. Lehmann P,
    3. Hahn HK,
    4. et al

    . Decreased hippocampal volume, indirectly measured, is associated with depressive symptoms and consolidation deficits in multiple sclerosis. Mult Scler 2011; 17: 1088– 97

    Abstract/FREE Full Text
37. 37.↵
    1. Derakhshan M,
    2. Caramanos Z,
    3. Giacomini PS,
    4. et al

    . Evaluation of automated techniques for the quantification of grey matter atrophy in patients with multiple sclerosis. Neuroimage 2010; 52: 1261– 67

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Morey RA,
    2. Petty CM,
    3. Xu Y,
    4. et al

    . A comparison of automated segmentation and manual tracing for quantifying hippocampal and amygdala volumes. Neuroimage 2009; 45: 855– 66

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Khalil M,
    2. Enzinger C,
    3. Langkammer C,
    4. et al

    . Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Mult Scler 2009; 15: 1048– 54

    Abstract/FREE Full Text
40. 40.↵
    1. Ceccarelli A,
    2. Rocca MA,
    3. Neema M,
    4. et al

    . Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis. Mult Scler 2009; 16: 39– 44

    PubMed
41. 41.↵
    1. Antulov R,
    2. Carone DA,
    3. Bruce J,
    4. et al

    . Regionally distinct white matter lesions do not contribute to regional gray matter atrophy in patients with multiple sclerosis. J Neuroimaging 2011; 21: 210– 18

    CrossRefPubMedWeb of Science